MA33304B1 - Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase - Google Patents

Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase

Info

Publication number
MA33304B1
MA33304B1 MA34398A MA34398A MA33304B1 MA 33304 B1 MA33304 B1 MA 33304B1 MA 34398 A MA34398 A MA 34398A MA 34398 A MA34398 A MA 34398A MA 33304 B1 MA33304 B1 MA 33304B1
Authority
MA
Morocco
Prior art keywords
oxazole
kinase inhibitors
substituted indazoles
compounds
indazoles
Prior art date
Application number
MA34398A
Other languages
Arabic (ar)
English (en)
Inventor
Julie Nicole Hamblin
Paul Spencer Jones
Suzanne Elaine Keeling
Joelle Le
Charlotte Jane Mitchell
Nigel James Parr
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33304B1 publication Critical patent/MA33304B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'invention porte sur certains nouveaux composés. De façon spécifique, l'invention porte sur des composés de formule (I) : et des sels de ceux-ci. Les composés de l'invention sont des inhibiteurs d'activité de kinase, en particulier d'activité de PI3-kinase.
MA34398A 2009-04-30 2010-04-28 Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase MA33304B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17403309P 2009-04-30 2009-04-30
PCT/EP2010/055666 WO2010125082A1 (fr) 2009-04-30 2010-04-28 Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase

Publications (1)

Publication Number Publication Date
MA33304B1 true MA33304B1 (fr) 2012-05-02

Family

ID=42225106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34398A MA33304B1 (fr) 2009-04-30 2010-04-28 Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase

Country Status (39)

Country Link
US (14) US8580797B2 (fr)
EP (3) EP3260453B1 (fr)
JP (1) JP5570589B2 (fr)
KR (2) KR101679642B1 (fr)
CN (1) CN102459253B (fr)
AR (2) AR076435A1 (fr)
AU (1) AU2010243613B2 (fr)
BR (1) BRPI1016219B8 (fr)
CA (1) CA2759476C (fr)
CL (1) CL2011002706A1 (fr)
CO (1) CO6390057A2 (fr)
CR (1) CR20110603A (fr)
CY (1) CY1119515T1 (fr)
DK (2) DK2899191T3 (fr)
DO (1) DOP2011000328A (fr)
EA (1) EA021056B1 (fr)
ES (3) ES2876933T3 (fr)
HR (2) HRP20150173T1 (fr)
HU (1) HUE034724T2 (fr)
IL (1) IL215803A (fr)
JO (1) JO3025B1 (fr)
LT (1) LT2899191T (fr)
MA (1) MA33304B1 (fr)
ME (2) ME02900B (fr)
MX (1) MX2011011534A (fr)
MY (1) MY160454A (fr)
NZ (1) NZ596071A (fr)
PE (1) PE20120321A1 (fr)
PL (2) PL2899191T3 (fr)
PT (2) PT2899191T (fr)
RS (2) RS56433B1 (fr)
SG (2) SG10201401881QA (fr)
SI (2) SI2899191T1 (fr)
SM (2) SMT201700481T1 (fr)
TW (3) TWI466884B (fr)
UA (1) UA101098C2 (fr)
UY (1) UY32585A (fr)
WO (1) WO2010125082A1 (fr)
ZA (1) ZA201107878B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280705B1 (fr) 2008-06-05 2014-10-08 Glaxo Group Limited Nouveaux composés
JP5502077B2 (ja) * 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
WO2010102958A1 (fr) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases
TWI466884B (zh) 2009-04-30 2015-01-01 Glaxo Group Ltd 6-(1h-吲哚-4-基)-4-(5-{[4-(1-甲基乙基)-1-哌嗪基]甲基}-1,3-噁唑-2-基)-1h-吲唑、其醫藥組合物及作為激酶活性抑制劑之用途
CN102372675B (zh) * 2010-08-14 2013-12-18 王娜 6-氯-4-碘吲唑及其制备方法与应用
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
US9102668B2 (en) 2010-09-08 2015-08-11 Glaxo Group Limited Polymorphs and salts
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AU2011326071A1 (en) * 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
AP3849A (en) 2011-12-15 2016-09-30 Novartis Ag Use of inhibitors of the activity or function of pi3k
AU2013259737A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CA2872014A1 (fr) 2012-05-08 2013-11-14 Lycera Corporation Tetrahydro[1,8]naphtyridine-sulfonamide et composes apparentes pour utilisation en tant qu'agonistes de ror.gamma. et dans le traitement d'une maladie
RU2015104962A (ru) * 2012-07-16 2016-09-10 Ньюропор Терапис, Инк. Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков
EP2914260A1 (fr) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour prévenir le syndrome des antiphospholipides (sapl)
WO2014098232A1 (fr) * 2012-12-21 2014-06-26 Yamashita Chikamasa Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire
AU2014336250A1 (en) * 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
WO2015055691A1 (fr) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095788A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
MX2016009581A (es) * 2014-01-24 2017-04-27 Abbvie Inc Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
US10226376B2 (en) 2014-03-19 2019-03-12 Purewick Corporation Apparatus and methods for receiving discharged urine
US10390989B2 (en) 2014-03-19 2019-08-27 Purewick Corporation Apparatus and methods for receiving discharged urine
US11376152B2 (en) 2014-03-19 2022-07-05 Purewick Corporation Apparatus and methods for receiving discharged urine
US10952889B2 (en) 2016-06-02 2021-03-23 Purewick Corporation Using wicking material to collect liquid for transport
US11806266B2 (en) 2014-03-19 2023-11-07 Purewick Corporation Apparatus and methods for receiving discharged urine
WO2015171610A2 (fr) 2014-05-05 2015-11-12 Lycera Corporation Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9127069B1 (en) * 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
CN104086538B (zh) * 2014-06-13 2016-07-06 南京药石科技股份有限公司 一种pi3k激酶抑制剂的中间体及其制备方法与应用
WO2016059220A1 (fr) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents d'activation du tcr à utiliser dans le traitement de la lla-t
CA2975997A1 (fr) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Composes pyrazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations desdits composes
WO2016179343A1 (fr) 2015-05-05 2016-11-10 Lycera Corporation Sulfonamides de dihydro-2h-benzo[b][1,4]oxazine et composés apparentés destinés à être utilisés comme agonistes de rorγ et pour le traitement de maladies
GB201509492D0 (en) * 2015-06-02 2015-07-15 Glaxosmithkline Ip Dev Ltd Novel processes
WO2016201225A1 (fr) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide et composés apparentés destinés à être utilisés comme agonistes de rorγ et pour le traitement de maladies
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
KR20180070697A (ko) 2015-10-27 2018-06-26 머크 샤프 앤드 돔 코포레이션 Ror감마t 저해제로서의 치환된 인다졸 화합물 및 이의 용도
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
BR112018014525A2 (pt) * 2016-01-14 2018-12-11 Handok Inc compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
US10376406B2 (en) 2016-07-27 2019-08-13 Purewick Corporation Male urine collection device using wicking material
US20190161480A1 (en) * 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
AU2018216821B2 (en) 2017-01-31 2020-05-07 Purewick Corporation Apparatus and methods for receiving discharged urine
JP7093852B2 (ja) 2018-05-01 2022-06-30 ピュアウィック コーポレイション 流体収集装置及びその使用方法
ES2912549T3 (es) 2018-05-01 2022-05-26 Purewick Corp Dispositivos de recogida de fluidos, sistemas relacionados y métodos relacionados
WO2019212950A1 (fr) 2018-05-01 2019-11-07 Purewick Corporation Dispositifs de collecte de fluide, systèmes associés et procédés associés
EP3787567A1 (fr) 2018-05-01 2021-03-10 Purewick Corporation Dispositifs, systèmes et procédés de collecte de fluide
EP4559443A3 (fr) 2020-01-03 2025-06-18 Purewick Corporation Dispositifs de collecte d'urine ayant une partie relativement large et une partie allongée et procédés associés
WO2021195384A1 (fr) 2020-03-26 2021-09-30 Purewick Corporation Dispositif de capture d'urine multicouche et procédés associés
WO2021211729A1 (fr) 2020-04-17 2021-10-21 Purewick Corporation Dispositifs de collecte de fluide, systèmes, et procédés de fixation solide d'une partie en saillie en position permettant l'utilisation
WO2021211801A1 (fr) 2020-04-17 2021-10-21 Purewick Corporation Ensembles de collecte de fluide comprenant une barrière imperméable aux fluides comportant une cuvette et une base
US12472090B2 (en) 2020-04-17 2025-11-18 Purewick Corporation Female external catheter devices having a urethral cup, and related systems and methods
WO2021216422A1 (fr) 2020-04-20 2021-10-28 Purewick Corporation Dispositifs de collecte de fluide réglables entre une orientation basée sur le vide et une orientation basée sur la gravité, et systèmes et procédés associés
US12048643B2 (en) 2020-05-27 2024-07-30 Purewick Corporation Fluid collection assemblies including at least one inflation device and methods and systems of using the same
WO2022031943A1 (fr) 2020-08-06 2022-02-10 Purewick Corporation Système de collecte de fluide comprenant un vêtement et un dispositif de collecte de fluide
US20220047410A1 (en) 2020-08-11 2022-02-17 Purewick Corporation Fluid collection assemblies defining waist and leg openings
EP4210643A1 (fr) 2020-09-09 2023-07-19 Purewick Corporation Dispositifs, systèmes et procédés de collecte de fluide
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
US11801186B2 (en) 2020-09-10 2023-10-31 Purewick Corporation Urine storage container handle and lid accessories
US12042423B2 (en) 2020-10-07 2024-07-23 Purewick Corporation Fluid collection systems including at least one tensioning element
US12440370B2 (en) 2020-10-21 2025-10-14 Purewick Corporation Apparatus with compressible casing for receiving discharged urine
US12257174B2 (en) 2020-10-21 2025-03-25 Purewick Corporation Fluid collection assemblies including at least one of a protrusion or at least one expandable material
US12208031B2 (en) 2020-10-21 2025-01-28 Purewick Corporation Adapters for fluid collection devices
US12569365B2 (en) 2020-10-21 2026-03-10 Purewick Corporation Fluid collection assemblies including at least one shape memory material disposed in the conduit
US12048644B2 (en) 2020-11-03 2024-07-30 Purewick Corporation Apparatus for receiving discharged urine
US12268627B2 (en) 2021-01-06 2025-04-08 Purewick Corporation Fluid collection assemblies including at least one securement body
JP2024503636A (ja) 2021-01-07 2024-01-26 ピュアウィック コーポレイション 車椅子に固定可能な尿収集システムおよび関連する方法
WO2022159392A1 (fr) 2021-01-19 2022-07-28 Purewick Corporation Dispositifs et systèmes de collecte de fluide à ajustement variable, et procédés de collecte de fluide associés
EP4274524B1 (fr) 2021-02-26 2024-08-28 Purewick Corporation Dispositif de collecte de fluide configuré comme un dispositif de collecte d'urine masculin
US12551385B2 (en) 2021-03-05 2026-02-17 Purewick Corporation Fluid collection assembly including a tube having porous wicking material for improved fluid transport
US12029677B2 (en) 2021-04-06 2024-07-09 Purewick Corporation Fluid collection devices having a collection bag, and related systems and methods
US12251333B2 (en) 2021-05-21 2025-03-18 Purewick Corporation Fluid collection assemblies including at least one inflation device and methods and systems of using the same
US12324767B2 (en) 2021-05-24 2025-06-10 Purewick Corporation Fluid collection assembly including a customizable external support and related methods
US12150885B2 (en) 2021-05-26 2024-11-26 Purewick Corporation Fluid collection system including a cleaning system and methods
US12575960B2 (en) 2021-06-24 2026-03-17 Purewick Corporation Urine collection systems having one or more of volume, pressure, or flow indicators, and related methods
US12551366B2 (en) 2021-08-02 2026-02-17 Purewick Corporation Fluid collection devices having multiple fluid collection regions, and related systems and methods
US20250059172A1 (en) 2021-12-28 2025-02-20 Nippon Shinyaku Co., Ltd. Indazole compound and pharmaceutical
WO2023147603A2 (fr) * 2022-01-31 2023-08-03 Intra-Cellular Therapies, Inc. Cristaux de sel
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
KR20250034289A (ko) 2022-05-02 2025-03-11 프리시릭스 엔.브이. 사전 표적화

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
CN1070849C (zh) 1994-06-15 2001-09-12 惠尔康基金会集团公司 酶抑制剂
GEP20002254B (en) 1995-04-14 2000-10-25 Glaxo Wellcome Inc Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
HK1043788A1 (zh) 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
JP4436041B2 (ja) 2000-08-05 2010-03-24 グラクソ グループ リミテッド 抗炎症剤としての６α，９α−ジフルオロ−１７α−［（２−フラニルカルボキシル）オキシ］−１１β−ヒドロキシ−１６α−メチル−３−オキソ−アンドロスト−１，４−ジエン−１７−チオカルボン酸Ｓ−フルオロメチルエステル
JP5089846B2 (ja) 2000-09-29 2012-12-05 グラクソ グループ リミテッド 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002067683A1 (fr) 2001-02-26 2002-09-06 Merck & Co., Inc. Inhibiteurs de la protease vih retenus sur des supports en resines d'echange de cations destines a l'administration par voie orale
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US7759373B2 (en) 2001-04-16 2010-07-20 Mitsubishi Tanabe Pharma Corporation Large conductance calcium-activated K channel opener
BR0209271A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
CA2452114C (fr) 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Promoteur de production/secretion de la superfamille des tgf-.beta.
SI1425001T1 (sl) 2001-09-14 2009-04-30 Glaxo Group Ltd Glaxo Welcome Fenetanolaminski derivati za zdravljenje respiratornih bolezni
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
WO2003051847A1 (fr) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Derives de (1-h-indazol-3-yl) -amide comme inhibiteurs de gsk-3
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
WO2003061651A1 (fr) 2002-01-22 2003-07-31 The Regents Of The University Of California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
ATE496620T1 (de) 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AU2003268064A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2495179A1 (fr) 2002-08-09 2004-02-19 Astrazeneca Ab Nouveaux composes
NZ538225A (en) 2002-08-09 2008-05-30 Astrazeneca Ab "1,2,4"Oxadiazoles as modulators of metabotropic glutamate receptor-5
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
CA2499150A1 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004029055A1 (fr) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Derives d'azole-pyrimidines fondues
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
EP1556342B1 (fr) 2002-10-28 2008-03-26 Glaxo Group Limited Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005016245A2 (fr) 2003-06-13 2005-02-24 Zentaris Gmbh Composes presentant une activite inhibitrice de la phosphatidylinositol 3-kinase
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1677795B1 (fr) 2003-10-14 2011-01-05 Glaxo Group Limited Antagonistes du recepteur muscarinique de l'acetylcholine
WO2005035506A1 (fr) * 2003-10-15 2005-04-21 Ube Industries, Ltd. Nouveau derive d'indazole
EP1699512B1 (fr) 2003-11-03 2012-06-20 Glaxo Group Limited Distributeur de fluides
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
AU2004299277A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
WO2005077368A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique iii
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
US20080227772A1 (en) 2004-02-04 2008-09-18 Neurosearch A/S Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
JP2007529464A (ja) 2004-03-16 2007-10-25 グラクソ　グループ　リミテッド ビラゾロ［３，４−ｂ］ピリジン化合物及びＰＤＥ４阻害剤としてのその使用
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006000401A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Oxazines substituees utilisees comme modulateurs du recepteur glucocorticoide
WO2006000398A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Derives de 2,3-benzoxazine utilises en tant que modulateurs non steroidiens du recepteur glucocorticoide
US20060013540A1 (en) 2004-07-19 2006-01-19 Chao Zhang Single fiber optical transceiver module
WO2006135383A2 (fr) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
ATE517882T1 (de) 2004-10-19 2011-08-15 Hoffmann La Roche Chinolinderivate
JP2008520700A (ja) 2004-11-18 2008-06-19 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法
AU2005311826A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1841780B1 (fr) 2005-01-10 2011-07-27 Glaxo Group Limited Derives d'androstane-17-alpha-carbonate pour utilisation dans le traitement de conditions allergiques et inflammatoires
US20090124588A1 (en) 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
WO2006089076A2 (fr) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides et analogues associes
BRPI0609485A2 (pt) 2005-03-31 2010-04-13 Ronen Kahana criação de aves domésticas e outros animais resistentes a doenças virais
US20060264433A1 (en) 2005-05-23 2006-11-23 Backes Bradley J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
TW200800946A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Substituted piperazines as metabotropic glutamate receptor antagonists
CA2619881A1 (fr) 2005-08-16 2007-02-22 Genzyme Corporation Composes se liant aux recepteurs de chimiokine
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AU2007245129A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
CA2644910C (fr) 2006-03-31 2014-01-28 Abbott Laboratories Composes d'indazole
JP2009532507A (ja) * 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｉ３キナーゼアンタゴニスト
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
WO2008016123A1 (fr) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
WO2008020229A2 (fr) 2006-08-17 2008-02-21 Astrazeneca Ab Composés chimiques
EP2054390B1 (fr) 2006-08-25 2012-04-11 Abbott Laboratories Dérivés d'indazole inhibant trpv1, et leur utilisation
US7948877B2 (en) * 2006-09-07 2011-05-24 Via Technologies, Inc. Systems and methods for packet forward control
CA2664342A1 (fr) 2006-09-25 2008-04-03 Sonia Escaich Nouveaux inhibiteurs de la synthese des heptoses bacteriennes, procedes pour leur elaboration, et applications biologiques de ces inhibiteurs
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
JP2010116389A (ja) 2008-10-17 2010-05-27 Bayer Cropscience Ag 殺虫性アリールピロリジン類
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP5588339B2 (ja) 2007-06-25 2014-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化学化合物
CL2008002199A1 (es) 2007-07-26 2009-10-23 Vitae Pharmaceuticals Inc Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
ES2399774T3 (es) 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
JP2009127226A (ja) * 2007-11-21 2009-06-11 Seiji Ohara 温水プールに雪を落し込む手段を持つ融雪装置
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
WO2009134387A1 (fr) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déhydrogénase 1
WO2009134384A1 (fr) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déhydrogénase 1
BRPI0911764A2 (pt) 2008-05-01 2015-10-06 Boehringer Ingelheim Int inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
WO2009147187A1 (fr) 2008-06-05 2009-12-10 Glaxo Group Limited Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
EP2280705B1 (fr) 2008-06-05 2014-10-08 Glaxo Group Limited Nouveaux composés
JP5535652B2 (ja) 2008-06-11 2014-07-02 浜松ホトニクス株式会社 ガラス溶着方法
WO2010127237A2 (fr) 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
KR20110050459A (ko) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
US8245111B2 (en) * 2008-12-09 2012-08-14 Intel Corporation Performing multi-bit error correction on a cache line
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20120039905A1 (en) 2009-01-13 2012-02-16 The Babraham Institute The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection
WO2010102958A1 (fr) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
TWI466884B (zh) 2009-04-30 2015-01-01 Glaxo Group Ltd 6-(1h-吲哚-4-基)-4-(5-{[4-(1-甲基乙基)-1-哌嗪基]甲基}-1,3-噁唑-2-基)-1h-吲唑、其醫藥組合物及作為激酶活性抑制劑之用途
CN102414175A (zh) 2009-04-30 2012-04-11 拜耳作物科学公司 杀虫的芳基吡咯烷
UA107080C2 (uk) 2009-04-30 2014-11-25 Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну
WO2011067366A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
US9102668B2 (en) 2010-09-08 2015-08-11 Glaxo Group Limited Polymorphs and salts
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US10642898B1 (en) * 2017-04-11 2020-05-05 Northrop Grumman Systems Corporation Three-dimensional graph

Also Published As

Publication number Publication date
PL2424864T3 (pl) 2015-05-29
DOP2011000328A (es) 2016-12-30
ME02053B (me) 2015-05-20
RS53830B1 (sr) 2015-06-30
US20120046286A1 (en) 2012-02-23
EP2424864B1 (fr) 2014-12-03
EA201190227A1 (ru) 2012-05-30
US20100280029A1 (en) 2010-11-04
SG10201401881QA (en) 2014-07-30
ES2644724T3 (es) 2017-11-30
CR20110603A (es) 2012-02-28
PT2899191T (pt) 2017-11-14
NZ596071A (en) 2013-12-20
US20130096117A1 (en) 2013-04-18
DK2899191T3 (da) 2017-11-13
US20190175608A1 (en) 2019-06-13
KR101771193B1 (ko) 2017-09-05
JP2012525349A (ja) 2012-10-22
US20170157136A1 (en) 2017-06-08
CL2011002706A1 (es) 2012-04-09
US20130029985A1 (en) 2013-01-31
BRPI1016219B8 (pt) 2021-05-25
ES2876933T3 (es) 2021-11-15
HRP20171450T1 (hr) 2017-11-17
US8586590B2 (en) 2013-11-19
SG175782A1 (en) 2011-12-29
TW201444832A (zh) 2014-12-01
CY1119515T1 (el) 2018-03-07
AU2010243613A1 (en) 2011-11-17
EA021056B1 (ru) 2015-03-31
MX2011011534A (es) 2012-02-28
DK2424864T3 (en) 2015-02-23
LT2899191T (lt) 2017-10-25
US20150328226A1 (en) 2015-11-19
ZA201107878B (en) 2013-04-24
JO3025B1 (ar) 2016-09-05
SI2424864T1 (sl) 2015-03-31
EP3260453B1 (fr) 2021-03-31
HK1209102A1 (en) 2016-03-24
CO6390057A2 (es) 2012-02-29
TW201604192A (zh) 2016-02-01
PE20120321A1 (es) 2012-04-19
UA101098C2 (xx) 2013-02-25
SMT201700481T1 (it) 2017-11-15
KR20120079852A (ko) 2012-07-13
IL215803A0 (en) 2012-01-31
HUE034724T2 (hu) 2018-02-28
CA2759476C (fr) 2018-10-09
US10946025B2 (en) 2021-03-16
PT2424864E (pt) 2015-02-27
SMT201500043B (it) 2015-05-05
US20170015656A1 (en) 2017-01-19
US20200206237A1 (en) 2020-07-02
HK1165801A1 (en) 2012-10-12
HRP20150173T1 (hr) 2015-05-22
US10624898B2 (en) 2020-04-21
EP2899191A1 (fr) 2015-07-29
BRPI1016219B1 (pt) 2020-09-01
US20130131080A1 (en) 2013-05-23
TWI562992B (en) 2016-12-21
MY160454A (en) 2017-03-15
CA2759476A1 (fr) 2010-11-04
TW201103927A (en) 2011-02-01
KR101679642B1 (ko) 2016-11-25
RS56433B1 (sr) 2018-01-31
BRPI1016219A2 (pt) 2016-04-26
US8586583B2 (en) 2013-11-19
US8575162B2 (en) 2013-11-05
PL2899191T3 (pl) 2018-01-31
TWI516487B (zh) 2016-01-11
AR108388A2 (es) 2018-08-15
US20140080830A1 (en) 2014-03-20
AU2010243613B2 (en) 2015-05-07
US20180325911A1 (en) 2018-11-15
UY32585A (es) 2010-11-30
ME02900B (fr) 2018-04-20
IL215803A (en) 2014-11-30
JP5570589B2 (ja) 2014-08-13
TWI466884B (zh) 2015-01-01
US8580797B2 (en) 2013-11-12
US8609657B2 (en) 2013-12-17
US10383879B2 (en) 2019-08-20
ES2531274T3 (es) 2015-03-12
AR076435A1 (es) 2011-06-08
WO2010125082A1 (fr) 2010-11-04
SI2899191T1 (sl) 2017-11-30
US20190328744A1 (en) 2019-10-31
EP2899191B1 (fr) 2017-08-09
US20100280045A1 (en) 2010-11-04
EP3260453A1 (fr) 2017-12-27
KR20160135852A (ko) 2016-11-28
CN102459253A (zh) 2012-05-16
EP2424864A1 (fr) 2012-03-07
CN102459253B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
MA33304B1 (fr) Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
EA201000113A1 (ru) Пиразольные соединения
EA201070480A1 (ru) Ингибиторы с-fms киназы
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA200970156A1 (ru) Пиридизиноновые производные
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201300052A1 (ru) [1,8]нафтиридиновые производные
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA201170922A1 (ru) Производные сульфонамида
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
EA201100503A1 (ru) Глюкозидные производные и их применения